Guess which ASX All Ords share just crashed 52% on a TGA update

Today was a day that shareholders of this medical diagnostics technology company won't forget in a hurry.

| More on:
A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Key points

  • This medical diagnostics technology company was sold off on Monday
  • This follows news that its TGA application for ColoSTAT has been withdrawn
  • ColoSTAT is a simple, low-cost, blood test for global mass market detection of colorectal cancer

The Rhythm Biosciences Ltd (ASX: RHY) share price had a day to forget on Monday.

The medical diagnostics technology's shares returned from a trading halt and crashed as much as 52% to 46 cents.

The ASX All Ords share ultimately recovered a touch and ended the day with a 38% decline to 59.5 cents.

Why did this ASX All Ords share get hammered?

Investors were hitting the sell button in a panic on Monday after the company was dealt a blow by the Australian Therapeutic Goods Administration (TGA).

According to an announcement, after the receipt and analysis of a thorough application review and its most recent engagement with the TGA, the company has decided to withdraw its current ColoSTAT application for an Australian Register of Therapeutic Goods (ARTG) listing.

Rhythm Biosciences' ColoSTAT product is a simple, low-cost, blood test for global mass market detection of colorectal cancer. It notes that worldwide, colorectal cancer is the third most common cancer in men and the second most common in women, accounting for an estimated 1.9 million new cases and 935,000 deaths annually.

Management advised that it is withdrawing its application because it simply does not have enough time to answer the regulator's questions within the necessary timeframe. This is because some questions will require new internal analytical testing and the TGA is reluctant to provide an extension beyond its 20 business days timeframe.

The good news is that this isn't the end of the road for ColoSTAT in Australia. Management intends to submit a new application with the TGA, in line to better meet their feedback and questions posed.  And while the company doesn't know when the new application will be submitted, it does expect it to be in the current calendar year.

Furthermore, this withdrawal does not impede the ASX All Ords share's proposed market entry activities into other CE Mark conforming territories and additional international markets, including the United States.

Management commentary

Rhythm Biosciences' Executive Chairman, Otto Buttula, was disappointed but remains positive on the future. Buttula said:

Having decided to withdraw RHY's current TGA submission for ColoSTAT is clearly disappointing for all stakeholders. Nonetheless, we appreciate the thorough review undertaken and meaningful dialogue with the TGA. Following the TGA's most recent feedback, both written and verbal and management / Board review, we believe that time constraints imposed result in a better opportunity for the Company to submit a new and strengthened application, in line with the questions raised in the TGA application review. Hence, with a new submission to be completed in line with the questions raised by the TGA, we believe we have a better blueprint to follow in framing our new application.

Therefore, I remain confident of a TGA registration for ColoSTAT in the future. Whilst Australia, as our home, remains important, it represents one of the smaller markets in our global aspirations and the Company has always intended to build the majority of its revenues in overseas territories. We look forward to keeping the market abreast of other positive developments in the near term.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Woman checking out new TVs.
Broker Notes

Does JP Morgan think JB Hi-Fi shares can keep rising?

The retailer is up 16% for the year to date.

Read more »

Happy young woman saving money in a piggy bank.
Share Market News

These ASX shares could pay you passive income for life

Analysts think these income shares could be top picks for Aussie investors.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Share Market News

3 excellent ASX ETFs for beginners to buy in FY26

Let's see why these funds could be top picks for Aussie's starting their investment journey.

Read more »

A trio of ASX shares analysts huddle together in an office with computer screens all around them showing share price movements
Opinions

2 of the best ASX 200 shares to buy right now

I think these stocks are excellent buys for the long-term.

Read more »

A man in his 30s with a clipped beard sits at his laptop on a desk with one finger to the side of his face and his chin resting on his thumb as he looks concerned while staring at his computer screen.
Broker Notes

Should you buy CBA, Telstra, and Wesfarmers shares?

Let's see what analysts are saying about these blue chips.

Read more »

Concept image of a businessman riding a bull on an upwards arrow.
Opinions

I'm very bullish on these 2 ASX stocks

I think these are two of the best ASX investments money can buy.

Read more »

A man looking at his laptop and thinking.
Share Market News

5 things to watch on the ASX 200 on Thursday

It looks likely to be a poor session for Aussie investors today.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »